Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes

Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adeno...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychiatric disease and treatment Vol. 19; pp. 2499 - 2509
Main Authors Jiang, Qiaona, Zhang, Xiaofei, Lu, Xiaohui, Li, Yanzhe, Lu, Chenghao, Chi, Jinghui, Ma, Yanyan, Shi, Xiaomei, Wang, Lili, Li, Shen
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 30.11.2023
Dove Medical Press
Subjects
Online AccessGet full text
ISSN1178-2021
1176-6328
1178-2021
DOI10.2147/NDT.S427557

Cover

Abstract Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients. Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of -flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively. Results: The combination of GSTM1 -rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1 -rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance. Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients. Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments
AbstractList Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients. Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of -flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively. Results: The combination of GSTM1 -rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1 -rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance. Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients. Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments
Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.ObjectiveTardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.MethodsTwo hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.The combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.ResultsThe combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients.ConclusionOur findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients.
Qiaona Jiang,1,* Xiaofei Zhang,1,* Xiaohui Lu,2 Yanzhe Li,3 Chenghao Lu,1 Jinghui Chi,1 Yanyan Ma,1 Xiaomei Shi,1 Lili Wang,1 Shen Li3 1Department of Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, People’s Republic of China; 2Department of Psychiatry, Qingdao Mental Health Center, Qingdao, People’s Republic of China; 3Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lili Wang, Department of Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, No. 13, Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel +00-86-022-88188796, Email tjadyywll@163.com Shen Li, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, No. 13, Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel +00-86-022-88188875, Email lishen@tmu.edu.cnObjective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.Results: The combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients.Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments
Audience Academic
Author Zhang, Xiaofei
Ma, Yanyan
Wang, Lili
Lu, Chenghao
Li, Yanzhe
Li, Shen
Lu, Xiaohui
Chi, Jinghui
Jiang, Qiaona
Shi, Xiaomei
Author_xml – sequence: 1
  givenname: Qiaona
  surname: Jiang
  fullname: Jiang, Qiaona
– sequence: 2
  givenname: Xiaofei
  surname: Zhang
  fullname: Zhang, Xiaofei
– sequence: 3
  givenname: Xiaohui
  surname: Lu
  fullname: Lu, Xiaohui
– sequence: 4
  givenname: Yanzhe
  surname: Li
  fullname: Li, Yanzhe
– sequence: 5
  givenname: Chenghao
  surname: Lu
  fullname: Lu, Chenghao
– sequence: 6
  givenname: Jinghui
  surname: Chi
  fullname: Chi, Jinghui
– sequence: 7
  givenname: Yanyan
  surname: Ma
  fullname: Ma, Yanyan
– sequence: 8
  givenname: Xiaomei
  surname: Shi
  fullname: Shi, Xiaomei
– sequence: 9
  givenname: Lili
  surname: Wang
  fullname: Wang, Lili
– sequence: 10
  givenname: Shen
  surname: Li
  fullname: Li, Shen
BookMark eNptkm9rUzEUhy8ywW36yi8QEEQYrUnun6S-G51uheGgra_Ducm5beZtUpNUrB_HT2puO2STkRcJJ895-CWcs-LEeYdF8ZbRMWeV-Pj1ajleVFzUtXhRnDIm5IhTzk4enV8VZzHeU1qKiZSnxZ9rdJisJotd1LhNtrW9TXuSPFlCMPYnkqt9_G4dRgsEnCFTv3I2DRezzRZs2KBLkVhHpuuBQnIDjiz02v7223VAZ-ETmfseie_I3S9r4NC7SAFjHM2xh4TmIL406HzMDjLHIYoPZAgXXxcvO-gjvnnYz4tvXz4vpzej27vr2fTydqSrRqRRU2pBa2OEBMkkVhpp14qOadPkQ1tpyktZtqaivBI166ipedW0lDFmOJRteV7Mjl7j4V5tg91A2CsPVh0KPqwUhPxVPaqKNaJlNQdGs1ijBFY3E5ndwnCBg-vD0bUN_scOY1Ibm_-378Gh30XF5aTOaXlVZfTdEV1BNlvX-RRAD7i6FELmeLJhmRo_Q-VlcGN1noLO5vqThvePGtYIfVpH3--S9S4-BS-OoA4-xoDdv6czqoapUnmq1MNUZZr9R2ubYJDmPLZ_tucvXEDRPA
CitedBy_id crossref_primary_10_1093_schbul_sbaf006
Cites_doi 10.1016/j.pnpbp.2006.12.019
10.1089/ars.2010.3603
10.3389/fphar.2021.834129
10.1038/364626a0
10.1038/sj.cr.7290272
10.1001/archpsyc.1973.01750340009001
10.1093/schbul/13.2.261
10.1146/annurev.pa.30.040190.002535
10.1176/jnp.7.2.223
10.1016/j.neuropharm.2011.01.048
10.1023/A:1005427323835
10.1097/01.fpc.0000184958.05775.66
10.1016/j.bbi.2022.01.006
10.1016/S0278-5846(00)00181-0
10.1034/j.1601-0825.2003.02866.x
10.1111/j.1748-1716.1990.tb08923.x
10.1007/s40120-018-0105-0
10.1097/MD.0000000000001507
10.1089/omi.2016.0003
10.4088/JCP.v68n0513
10.1016/j.schres.2006.12.019
10.1016/j.bbamem.2010.12.001
10.2147/NDT.S205014
10.1093/schbul/sbp006
10.1111/j.1749-6632.1989.tb14918.x
10.1076/jcen.20.3.310.823
10.1139/H07-081
10.1093/nar/19.19.5444
10.2165/00023210-200317010-00004
10.1042/bj3240025
10.1097/00008877-200105000-00006
10.1017/S1461145707008401
10.1093/schbul/sbv167
10.1016/j.jpsychires.2022.04.029
10.1155/2022/5748924
10.1007/s11920-007-0041-7
10.1155/2021/8881770
10.1177/070674370505000907
10.1007/s00702-004-0118-y
10.1001/archpsyc.1982.04290040080012
10.1080/j.1440-1614.2000.00737.x
10.1016/j.pnpbp.2012.10.018
10.1016/0006-3223(90)90461-A
10.1086/518312
10.1038/s41398-021-01471-y
10.1016/0006-3223(90)90490-S
10.2147/NDT.S235043
10.1006/abbi.2001.2630
10.1016/j.ajp.2021.102877
10.4088/JCP.16r10832
ContentType Journal Article
Copyright COPYRIGHT 2023 Dove Medical Press Limited
2023 Jiang et al.
Copyright_xml – notice: COPYRIGHT 2023 Dove Medical Press Limited
– notice: 2023 Jiang et al.
DBID AAYXX
CITATION
7X8
DOA
DOI 10.2147/NDT.S427557
DatabaseName CrossRef
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1178-2021
EndPage 2509
ExternalDocumentID oai_doaj_org_article_4167b152a10b4cce8a15698d407d27eb
A778111861
10_2147_NDT_S427557
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
0YH
123
29N
2WC
53G
5VS
7RV
7X7
8AO
8FE
8FH
8FI
8FJ
8G5
AAFWJ
AAYXX
ABIVO
ABUWG
ACGFO
ADBBV
ADRAZ
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BKEYQ
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DIK
DWQXO
E3Z
EBD
EBS
EJD
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
IHW
IPNFZ
IPY
ITC
KQ8
LK8
M2M
M2O
M48
M7P
NAPCQ
O5R
O5S
OK1
P2P
P6G
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSYQQ
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
PMFND
7X8
PPXIY
PQGLB
PUEGO
ID FETCH-LOGICAL-c467t-63c705dd78a818e4ce0fb7f1cd60fbb4c02383bd4024751f0d5246b0111d2a3b3
IEDL.DBID M48
ISSN 1178-2021
1176-6328
IngestDate Wed Aug 27 01:28:26 EDT 2025
Fri Sep 05 09:24:31 EDT 2025
Tue Jun 17 22:27:31 EDT 2025
Tue Jun 10 21:15:57 EDT 2025
Thu May 22 21:06:09 EDT 2025
Thu Apr 24 23:03:47 EDT 2025
Tue Jul 01 04:35:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License https://creativecommons.org/licenses/by-nc/3.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c467t-63c705dd78a818e4ce0fb7f1cd60fbb4c02383bd4024751f0d5246b0111d2a3b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/4167b152a10b4cce8a15698d407d27eb
PQID 2895705244
PQPubID 23479
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_4167b152a10b4cce8a15698d407d27eb
proquest_miscellaneous_2895705244
gale_infotracmisc_A778111861
gale_infotracacademiconefile_A778111861
gale_healthsolutions_A778111861
crossref_primary_10_2147_NDT_S427557
crossref_citationtrail_10_2147_NDT_S427557
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20231130
PublicationDateYYYYMMDD 2023-11-30
PublicationDate_xml – month: 11
  year: 2023
  text: 20231130
  day: 30
PublicationDecade 2020
PublicationTitle Neuropsychiatric disease and treatment
PublicationYear 2023
Publisher Dove Medical Press Limited
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Dove Medical Press
References Hitzeroth (ref41) 2007; 31
Cho (ref17) 2013; 46
Leucht (ref31) 2016; 42
Turcin (ref30) 2016; 20
Boison (ref28) 2012; 62
Huang (ref40) 2022; 2022
Tsermpini (ref5) 2021; 12
Howes (ref11) 2009; 35
Yao (ref50) 2011; 15
Gomes (ref52) 2011; 1808
Carbon (ref2) 2017; 78
Miao (ref29) 2019; 15
Radak (ref19) 2007; 32
Gronau (ref43) 2003; 9
Ignarro (ref46) 1990; 30
Liang (ref4) 2022; 151
Cadet (ref13) 1989; 570
Hensley (ref12) 2002; 397
Ng (ref14) 2008; 11
Wang (ref25) 2015; 94
Kruk (ref9) 1995; 7
Ermakov (ref53) 2021; 2021
Margolese (ref6) 2005; 50
Lipton (ref22) 1993; 364
Lahiri (ref36) 1991; 19
Baez (ref20) 1997; 324
McNeill (ref45) 2022; 101
Thelma (ref18) 2007; 92
Lohr (ref15) 1990; 28
Cadet (ref16) 1990; 28
Shi (ref37) 2005; 15
Zhang (ref44) 2007; 68
Toda (ref51) 2007; 9
Wang (ref27) 2004; 111
Sachdev (ref10) 2000; 34
Freedman (ref1) 1973; 28
Lim (ref39) 2021; 11
Liou (ref26) 2006; 16
Lohr (ref8) 2003; 17
Randolph (ref34) 1998; 20
Furchgott (ref47) 1990; 139
Kay (ref33) 1987; 13
Robinson (ref21) 1998; 21
Lou (ref38) 2007; 80
Zhang (ref35) 2009; 28
Mahadik (ref49) 2001; 25
Ward (ref7) 2018; 7
Zhang (ref42) 2020; 99
Naidu (ref48) 2001; 12
Uludag (ref3) 2021; 66
Uludag (ref24) 2022; 2022
Johnson (ref32) 1982; 39
Yan (ref23) 2020; 16
References_xml – volume: 31
  start-page: 664
  year: 2007
  ident: ref41
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2006.12.019
– volume: 15
  start-page: 2011
  year: 2011
  ident: ref50
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3603
– volume: 12
  start-page: 834129
  year: 2021
  ident: ref5
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2021.834129
– volume: 364
  start-page: 626
  year: 1993
  ident: ref22
  publication-title: Nature
  doi: 10.1038/364626a0
– volume: 15
  start-page: 97
  year: 2005
  ident: ref37
  publication-title: Cell Res
  doi: 10.1038/sj.cr.7290272
– volume: 28
  start-page: 463
  year: 1973
  ident: ref1
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1973.01750340009001
– volume: 13
  start-page: 261
  year: 1987
  ident: ref33
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/13.2.261
– volume: 30
  start-page: 535
  year: 1990
  ident: ref46
  publication-title: Annu Rev Pharmacol Toxicol
  doi: 10.1146/annurev.pa.30.040190.002535
– volume: 7
  start-page: 223
  year: 1995
  ident: ref9
  publication-title: J Neuropsychiatry Clin Neurosci
  doi: 10.1176/jnp.7.2.223
– volume: 62
  start-page: 1527
  year: 2012
  ident: ref28
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2011.01.048
– volume: 28
  start-page: 865
  year: 2009
  ident: ref35
  publication-title: J Chin Ment Health
– volume: 21
  start-page: 598
  year: 1998
  ident: ref21
  publication-title: J Inherit Metab Dis
  doi: 10.1023/A:1005427323835
– volume: 16
  start-page: 151
  year: 2006
  ident: ref26
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/01.fpc.0000184958.05775.66
– volume: 101
  start-page: 275
  year: 2022
  ident: ref45
  publication-title: Brain Behav Immun
  doi: 10.1016/j.bbi.2022.01.006
– volume: 25
  start-page: 463
  year: 2001
  ident: ref49
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/S0278-5846(00)00181-0
– volume: 9
  start-page: 62
  year: 2003
  ident: ref43
  publication-title: Oral Dis
  doi: 10.1034/j.1601-0825.2003.02866.x
– volume: 139
  start-page: 257
  year: 1990
  ident: ref47
  publication-title: Acta Physiol Scand
  doi: 10.1111/j.1748-1716.1990.tb08923.x
– volume: 7
  start-page: 233
  year: 2018
  ident: ref7
  publication-title: Neurol Ther
  doi: 10.1007/s40120-018-0105-0
– volume: 94
  start-page: e1507
  year: 2015
  ident: ref25
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000001507
– volume: 20
  start-page: 283
  year: 2016
  ident: ref30
  publication-title: OMICS
  doi: 10.1089/omi.2016.0003
– volume: 68
  start-page: 754
  year: 2007
  ident: ref44
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v68n0513
– volume: 92
  start-page: 278
  year: 2007
  ident: ref18
  publication-title: Schizophr Res
  doi: 10.1016/j.schres.2006.12.019
– volume: 1808
  start-page: 1380
  year: 2011
  ident: ref52
  publication-title: Biochimica et Biophysica Acta
  doi: 10.1016/j.bbamem.2010.12.001
– volume: 15
  start-page: 2451
  year: 2019
  ident: ref29
  publication-title: Neuropsychiatr Dis Treat
  doi: 10.2147/NDT.S205014
– volume: 35
  start-page: 549
  year: 2009
  ident: ref11
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbp006
– volume: 570
  start-page: 176
  year: 1989
  ident: ref13
  publication-title: Ann N Y Acad Sci
  doi: 10.1111/j.1749-6632.1989.tb14918.x
– volume: 20
  start-page: 310
  year: 1998
  ident: ref34
  publication-title: J Clin Exp Neuropsychol
  doi: 10.1076/jcen.20.3.310.823
– volume: 32
  start-page: 942
  year: 2007
  ident: ref19
  publication-title: Appl Physiol Nutr Metab
  doi: 10.1139/H07-081
– volume: 19
  start-page: 5444
  year: 1991
  ident: ref36
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/19.19.5444
– volume: 17
  start-page: 47
  year: 2003
  ident: ref8
  publication-title: CNS Drugs
  doi: 10.2165/00023210-200317010-00004
– volume: 324
  start-page: 25
  year: 1997
  ident: ref20
  publication-title: Biochem J
  doi: 10.1042/bj3240025
– volume: 12
  start-page: 209
  year: 2001
  ident: ref48
  publication-title: Behav Pharmacol
  doi: 10.1097/00008877-200105000-00006
– volume: 11
  start-page: 851
  year: 2008
  ident: ref14
  publication-title: Int J Neuropsychopharmacol
  doi: 10.1017/S1461145707008401
– volume: 42
  start-page: S90
  year: 2016
  ident: ref31
  publication-title: Schizophr Bull
  doi: 10.1093/schbul/sbv167
– volume: 151
  start-page: 181
  year: 2022
  ident: ref4
  publication-title: J Psychiatr Res
  doi: 10.1016/j.jpsychires.2022.04.029
– volume: 2022
  start-page: 5748924
  year: 2022
  ident: ref24
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2022/5748924
– volume: 9
  start-page: 329
  year: 2007
  ident: ref51
  publication-title: Curr Psychiatry Rep
  doi: 10.1007/s11920-007-0041-7
– volume: 2021
  start-page: 8881770
  year: 2021
  ident: ref53
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2021/8881770
– volume: 50
  start-page: 541
  year: 2005
  ident: ref6
  publication-title: Can J Psychiatry
  doi: 10.1177/070674370505000907
– volume: 111
  start-page: 623
  year: 2004
  ident: ref27
  publication-title: Journal of Neural Transmission
  doi: 10.1007/s00702-004-0118-y
– volume: 39
  start-page: 486
  year: 1982
  ident: ref32
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.1982.04290040080012
– volume: 34
  start-page: 355
  year: 2000
  ident: ref10
  publication-title: Aust N Z J Psychiatry
  doi: 10.1080/j.1440-1614.2000.00737.x
– volume: 2022
  start-page: 1075440
  year: 2022
  ident: ref40
  publication-title: Oxid Med Cell Longev
– volume: 46
  start-page: 207
  year: 2013
  ident: ref17
  publication-title: Prog Neuropsychopharmacol Biol Psychiatry
  doi: 10.1016/j.pnpbp.2012.10.018
– volume: 28
  start-page: 738
  year: 1990
  ident: ref16
  publication-title: Biol Psychiatry
  doi: 10.1016/0006-3223(90)90461-A
– volume: 80
  start-page: 1125
  year: 2007
  ident: ref38
  publication-title: Am J Hum Genet
  doi: 10.1086/518312
– volume: 11
  start-page: 351
  year: 2021
  ident: ref39
  publication-title: Transl Psychiatry
  doi: 10.1038/s41398-021-01471-y
– volume: 99
  start-page: e54
  year: 2020
  ident: ref42
  publication-title: Medicine
– volume: 28
  start-page: 535
  year: 1990
  ident: ref15
  publication-title: Biol Psychiatry
  doi: 10.1016/0006-3223(90)90490-S
– volume: 16
  start-page: 479
  year: 2020
  ident: ref23
  publication-title: Neuropsychiatr Dis Treat
  doi: 10.2147/NDT.S235043
– volume: 397
  start-page: 377
  year: 2002
  ident: ref12
  publication-title: Arch Biochem Biophys
  doi: 10.1006/abbi.2001.2630
– volume: 66
  start-page: 102877
  year: 2021
  ident: ref3
  publication-title: Asian J Psychiatr
  doi: 10.1016/j.ajp.2021.102877
– volume: 78
  start-page: e264
  year: 2017
  ident: ref2
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.16r10832
SSID ssj0037988
Score 2.3379261
Snippet Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia...
Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We...
Qiaona Jiang,1,* Xiaofei Zhang,1,* Xiaohui Lu,2 Yanzhe Li,3 Chenghao Lu,1 Jinghui Chi,1 Yanyan Ma,1 Xiaomei Shi,1 Lili Wang,1 Shen Li3 1Department of...
SourceID doaj
proquest
gale
crossref
SourceType Open Website
Aggregation Database
Enrichment Source
Index Database
StartPage 2499
SubjectTerms adenosine receptor
Cell receptors
Cognition disorders
cognitive impairments
Development and progression
Drug therapy
Genetic aspects
Health aspects
Oxidative stress
Physiological aspects
polymorphisms
Risk factors
Schizophrenia
Single nucleotide polymorphisms
Tardive dyskinesia
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9RAEF6kD8UXqVXp1VpHKAhCbLLZZHN9O1vLKbSCd4W-LfsTjpZELndi_x3_Umc2ueMOLL74FnaHsNlvZ2eGzHzD2EkQFc-tLJOAxi0RkueJiZVcoSpECEOfx16HV9fl-EZ8vS1uN1p9UU5YRw_cbdwpOgzSoJHRWWqEtb7SGHEMK4eBiOPSG7p902G6Cqa6OzgnFq6uGo_68JxeX0w_TgSXBVmhDfsTafofu4yjhbncY8961xBG3ZKesye-3me7V_3P7xfsN1FE4xxMlm1MRol5rQ-waGBKOP_0cPHQ3lEe-0yDrh2cr3KD4Atq_Wwey9lgVgN1zfath7GuYbKZdncG35t7D02Ab79mLpKCwySWkyQxbc67-OKRI45xfAeg24lLaeZAi2tfspvLz9PzcdK3WEgs3pCLpESc0sI5WWm03F5YnwYjQ2ZdiQ-44WTSc4O7zYUsspC6govSUIN6x3Vu8ldsp25qf8DABIljwum8cEKLUpdZFrg3QgfUemMG7MNq45Xt-cepDca9wjiEUFKIkupRGrCTtfCPjnbj72KfCMG1CHFlxwE8Qao_QepfJ2jA3hL-qis8XWu8Gkmqws2qMhuw91GCdB6XbHVfuoAfTuxZW5JHW5Koq3Zr-t3qjCmaogS32jfLVmHcWyAS6Gwd_o9ves2ecoSu46g8YjuL-dK_Qe9pYY6jovwBUOQYZQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes
URI https://www.proquest.com/docview/2895705244
https://doaj.org/article/4167b152a10b4cce8a15698d407d27eb
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEF_uAeIX8YnVs45wIAg5m2STzQkivRdVaJVrC_227GZ3pVgSTVq5_jv-pc5s0mLlBL-F7CTsZmbnkZ35DWPHjmdRnIs0cGjcAi6iONC-kstlCXfu1Ma-1-FwlA6m_NMsme2xTTPO9gPWt4Z21E9qWi1Obn6sP-CGf09pzCEXb0cXk5Mxj0SSiH12iCYppShsyLfHCTGBcjVdVkgsorAp1Pv74R3T5BH8_6WnvfG5us_utV4j9Bs2P2B7tnjI7gzbc_FH7BehR-MYjFe1z1PxKa9rWJYwIRH4aeFiXX-jFPe5AlUYON-kDcFHVAjzyle6wbwAaqhtawsDVcD4z4y8d3BdLiyUDj7fzI3HC4exrzQJfEadNf7FfUPw4_gOQI8Up1JWQJOrH7Pp1eXkfBC03ReCHJXnMkiRhb3EGJEpNOqW57bntHBhblK80Dwnax9rgwEoF0noeiaJeKqpd72JVKzjJ-ygKAv7lIF2Au9xo-LEcMVTlYahi6zmyqFC0LrD3mw-vMxbaHLqkLGQGKIQlyRySbZc6rDjLfH3BpHjdrIz4uCWhGC0_Y2y-irbXSlJVDR6MCrs4YJymykMZ08zXJMwkbA4sZfEf9nUpG6VgewLKtANszTssNeeggQUp5yrtqoBF07AWjuURzuUuI3zneFXGxmTNES5b4UtV7XEkDhBTqAf9uz_lv6c3UUhjxuAyiN2sKxW9gW6TkvdZftiJrrs8Oxy9OW6639AdP1W-Q0HbhnJ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+Susceptibility+to+Tardive+Dyskinesia+and+Cognitive+Impairments+in+Chinese+Han+Schizophrenia%3A+Role+of+Oxidative+Stress-Related+and+Adenosine+Receptor+Genes&rft.jtitle=Neuropsychiatric+disease+and+treatment&rft.au=Jiang%2C+Qiaona&rft.au=Zhang%2C+Xiaofei&rft.au=Lu%2C+Xiaohui&rft.au=Li%2C+Yanzhe&rft.date=2023-11-30&rft.issn=1178-2021&rft.eissn=1178-2021&rft.volume=19&rft.spage=2499&rft.epage=2509&rft_id=info:doi/10.2147%2FNDT.S427557&rft.externalDBID=n%2Fa&rft.externalDocID=10_2147_NDT_S427557
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-2021&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-2021&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-2021&client=summon